Tempus AI (NASDAQ:TEM) Given New $98.00 Price Target at HC Wainwright

Key Points

• HC Wainwright raised Tempus AI's price target from $90.00 to $98.00, suggesting a potential upside of 10.39% from the current price.
• Tempus AI reported earnings with a small beat, posting ($0.22) EPS compared to the consensus estimate of ($0.23) and a revenue of $314.64 million, up 89.5% year-over-year.
• Insider selling became notable as CEO Eric P. Lefkofsky sold 332,500 shares for approximately $24.6 million, decreasing his ownership by 3.49%.

Tempus AI (NASDAQ:TEM - Get Free Report) had its price objective raised by investment analysts at HC Wainwright from $90.00 to $98.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 10.39% from the company's current price.

Other equities analysts have also issued reports about the stock. Needham & Company LLC reissued a "buy" rating and issued a $70.00 target price on shares of Tempus AI in a report on Friday, August 8th. Bank of America raised their target price on shares of Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a report on Wednesday, June 25th. Guggenheim raised their target price on shares of Tempus AI from $65.00 to $75.00 and gave the company a "buy" rating in a report on Monday, June 30th. Piper Sandler reissued a "neutral" rating on shares of Tempus AI in a report on Friday, August 8th. Finally, BTIG Research raised their price target on shares of Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, August 20th. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $70.17.

Tempus AI Price Performance

TEM stock opened at $88.78 on Friday. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. Tempus AI has a 12 month low of $31.36 and a 12 month high of $91.45. The firm has a market cap of $15.42 billion, a P/E ratio of -74.61 and a beta of 5.08. The company's 50-day moving average price is $67.09 and its two-hundred day moving average price is $59.42.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The firm had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. During the same period last year, the firm earned ($6.86) EPS. The business's quarterly revenue was up 89.5% compared to the same quarter last year. Tempus AI has set its FY 2025 guidance at EPS. On average, analysts anticipate that Tempus AI will post -6.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Eric P. Lefkofsky sold 332,500 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $74.10, for a total value of $24,638,250.00. Following the sale, the chief executive officer directly owned 9,207,533 shares in the company, valued at approximately $682,278,195.30. This trade represents a 3.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Ryan Fukushima sold 17,460 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $1,303,389.00. Following the completion of the sale, the chief operating officer owned 839,180 shares in the company, valued at approximately $62,644,787. The trade was a 2.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 903,104 shares of company stock worth $63,733,330 in the last quarter. Corporate insiders own 26.27% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its holdings in Tempus AI by 35.9% in the 1st quarter. ARK Investment Management LLC now owns 7,501,399 shares of the company's stock valued at $361,867,000 after buying an additional 1,981,755 shares during the last quarter. Vanguard Group Inc. raised its holdings in Tempus AI by 6,247.5% in the 1st quarter. Vanguard Group Inc. now owns 5,995,117 shares of the company's stock valued at $289,204,000 after buying an additional 5,900,668 shares during the last quarter. Nikko Asset Management Americas Inc. raised its holdings in Tempus AI by 31.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,260,553 shares of the company's stock valued at $205,401,000 after buying an additional 1,021,460 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in Tempus AI by 31.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,255,477 shares of the company's stock valued at $205,284,000 after buying an additional 1,016,384 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Tempus AI in the 2nd quarter valued at approximately $54,020,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.